Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50905
Name inflammatory myofibroblastic tumor
Definition A mesenchymal cell neoplasm that has_material_basis_in myofibroblastic cells admixed with inflammatory cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer mesenchymal cell neoplasm inflammatory myofibroblastic tumor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ALK fusion Crizotinib inflammatory myofibroblastic tumor sensitive detail...
EML4 - ALK Crizotinib inflammatory myofibroblastic tumor predicted - sensitive detail...
ALK rearrange Ceritinib inflammatory myofibroblastic tumor sensitive detail...
ALK rearrange Crizotinib inflammatory myofibroblastic tumor sensitive detail...
ALK rearrange Brigatinib inflammatory myofibroblastic tumor sensitive detail...
ALK rearrange Lorlatinib inflammatory myofibroblastic tumor sensitive detail...
EML4 - ALK Alectinib inflammatory myofibroblastic tumor predicted - sensitive detail...
ALK rearrange Alectinib inflammatory myofibroblastic tumor sensitive detail...
ALK positive Alectinib inflammatory myofibroblastic tumor predicted - sensitive detail...
EML4 - ALK ALK I1171N Alectinib inflammatory myofibroblastic tumor predicted - resistant detail...
EML4 - ALK ALK I1171N Lorlatinib inflammatory myofibroblastic tumor predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT04925609 Phase Ib/II Brigatinib Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED) Recruiting NLD | FRA 0